At a glance
ClinicalIndex Comparison RecordN/ACompleted· 230 enrolled
Drug / intervention
Resolute Integrity Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm
In Brief
A clinical study evaluating Resolute Integrity Stent for Coronary Artery Disease. Completed, enrolled 230 participants across 1 site.
Detailed Summary
The purpose of this post approval study is to conduct a prospective, multicenter evaluation of the procedural and clinical outcomes of subjects that are treated with the commercially available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionJun 2014
Study CompletionJun 2015
TodayJul 2026
First PostedJul 11, 2012
Enrollment StartJul 1, 2012
Primary CompletionJun 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.0 years ago
Interventions
Resolute Integrity Stentdevice
Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System